UHPLC/MS Analysis of NBOMe Designer Drugs in Urine on Ascentis® Express C18 after Solid Phase Extraction (SPE) using Supel™-Select HLB

UHPLC/MS Analysis of NBOMe Designer Drugs in Urine on Ascentis® Express C18 after Solid Phase Extraction (SPE) using Supel™-Select HLB

Conditions

sample preparation SPE (Solid Phase Extraction)
sample/matrix human trine spiked at 100 ng/mL each compound
SPE well plate Supel-Select HLB 96-well pate, 30 mg/well (575661-U)
condition 1 mL methanol followed by 1 mL water
sample addition 1 mL
washing 1 mL water followed by 1 mL water:methanol (75:25)
eluate post-treatment evaporate sample to dryness and reconstitute in 1 mL water:acetonitrile (50:50)
column Ascentis Express C18, 10 cm x 3 mm I.D., 2 µm particles (50819-U)
column temp. 50 C
mobile phase [A] 20 mM ammonium acetate, pH 4 with acetic acid; [B] acetonitrile; (60:40, A:B)
flow rate 0.8 ml/min
pressure 7700 psi (531 bar)
injection 1 µl
detector UV, 280 nm

Description

Analysis Note The NBOMe designer drugs comprise various derivatives of the 2C family of illicit psychoactive phenethylamines. Shown here is a rapid sample preparation method for extraction of NBOMe drugs from human urine for LC/MS analysis.  NBOMe standards were acquired from Cerilliant and optimized reversed phase chromatographic conditions were developed on an Ascentis Express C18 2.0 μm column. Sample preparation of spiked human urine was carried out on Supel-Select HLB in a 96-well format. Absolute recovery data was determined. Cerilliant CRMs provided reliable quantification and The highest quality LC-MS solvents gave clean and robust operation.
Categories Analytical Chromatography, Forensics and Toxicology, Drugs of Abuse, drugs of abuse
Featured Industry Forensics and Toxicology
Legal Information Ascentis is a registered trademark of Sigma-Aldrich Co. LLC, Supel is a trademark of Sigma-Aldrich Co. LLC
suitability application for SPE, application for UHPLC-MS

Materials

     
Related Links